Skip to main content

You will need to login before you can apply for a job.

Director, Regulatory Affairs

Employer
Precision BioSciences, Inc.
Location
Durham, NC
Start date
Nov 7, 2024
View more categoriesView less categories
Discipline
Regulatory, Regulatory Affairs
Required Education
Masters Degree/MBA
Position Type
Full time
Hotbed
Bio NC

Job Details

Summary

The Director, Regulatory Affairs will focus on leading corporate regulatory strategies as well as executing tactical regulatory functions. Specific job functions include regulatory support of the global development and registration of the company’s products, drafting and submission of regulatory documents, license renewals, periodic updates and registrations to regulatory agencies. This role will organize regulatory information and track and control submissions, review and advise on labeling for compliance with regulatory filings, review product changes for impact on regulatory filings worldwide, and research regulatory issues and provide guidance and advice to colleagues. Externally, the Director, Regulatory Affairs will interface with regulatory agencies, corporate partners, consultants and vendors with regards to development, regulatory and registration strategies.

Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.

  • Serves as Regulatory Affairs subject matter expert and program team member for the development and implementation of regulatory strategy for gene therapy programs, as assigned
  • Drafts plans, content, and timelines as well as guides subject matter experts (SMEs) on the preparation of IND and BLA submissions and amendments to FDA with an overall objective to receive approval within the shortest time frames possible
  • Responsible for the quality of the submissions and critically reviews all documents prior to submission to ensure thoroughness and quality
  • Actively pursues use of expedited approaches to help advance programs through clinical development
  • Develops strategy for health authority meetings, develops contents, and manages meetings with FDA (e.g. pre-IND, EOPI/II, pre-BLA) and other health authorities to expedite development programs
  • Interacts with internal and external stakeholders, including FDA and other external regulatory and quality agencies, to collect and share information
  • Acts as main liaison with health authorities, as assigned, and submits controlled correspondence to FDA/other health authority on specific issues as needed
  • Coordinates with internal departments and CRO partners for preparation of required clinical documents (e.g. Investigator Brochures, Informed Consent forms)
  • Leads the development and implementation of regulatory initiatives from pre-IND through approval/commercialization and post-approval activities
  • Monitors impact of changing regulations on submission strategies and updates internal stakeholders accordingly
  • Works with QA on regulatory compliance issues, as needed
  • Independently applies the appropriate regulatory guidance or guideline documents and regulations to judge the appropriateness of solutions
  • Identifies and uses appropriate methods to collect the needed information to allow analysis and reach conclusions
  • Shows good judgment to determine when to escalate problems to his/her supervisor

Education/Experience

Required:

  • Ph.D. or Masters Degree (MS/MA) in biological sciences with 15+ years of regulatory affairs experience or equivalent combination of education and experience
  • Working knowledge and experience with 21 CFR, cGCPs, cGLPs, and cGMPs
  • Knowledge of GCPs, ICH guidelines and FDA regulations and familiarity with EMA/CHMP regulations and guidelines, and other international regulatory requirements
  • Technical writing proficiency and proofreading abilities
  • Track record in working successfully on IND/CTA and BLA/MAA applications to and health authority meetings with, the FDA/EMA
  • Expert knowledge in authoring or assembling and submitting technical files/regulatory dossiers to the regulatory agencies such as the FDA and EMA including eCTD format and eSubmissions
  • Strong computer skills in order to learn new programs as quickly as possible; experience in MS Word, Excel, Outlook and Adobe Acrobat is a must
  • Ability to communicate effectively both verbally and in writing
  • Strong personal and interpersonal skills, including the ability to relate to and negotiate with others while maintaining composure and acting with integrity and credibility to build trust.

Preferred:

  • Advanced therapy experience
  • Gene therapy experience

Travel Requirements

  • Some travel is expected for this position. If remote, the incumbent would be expected to travel to Durham, NC monthly.

Location

  • This is an office-based position located at the main headquarters in Durham, NC. This role will be able to function remotely in accordance with company guidelines but is subject to change as needed.

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing in vivo gene correction therapies for genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs. For additional information, please visit www. precisionbiosciences.com

Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

Company

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Company info
Website
Phone
919-314-5512
Location
302 East Pettigrew Street
Durham
North Carolina
27701
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert